ELTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
10.4M
-1.6%
10.6M
+19.9%
8.8M
+9.9%
8.0M
-20.3%
10.1M
R&D
6.8M
+0.8%
6.8M
+33.0%
5.1M
+0.8%
5.0M
-28.1%
7.0M
SG&A
3.6M
-5.9%
3.8M
+2.2%
3.8M
+25.1%
3.0M
-2.6%
3.1M
Operating Income
-10429000
+1.6%
-10602000
-19.9%
-8842000
-9.9%
-8045000
+20.3%
-10091000
EBITDA
-10393000
+1.5%
-10556000
-20.1%
-8793000
-10.0%
-7996000
+20.3%
-10038000
Net Income
-8217000
+30.5%
-11823000
-53.2%
-7718000
+23.5%
-10083000
+4.5%
-10561000
EPS (Basic)
$-0.43
+33.8%
$-0.65
-30.0%
$-0.50
+16.7%
$-0.60
+9.1%
$-0.66
EPS (Diluted)
$-0.43
+33.8%
$-0.65
-30.0%
$-0.50
+16.7%
$-0.60
+9.1%
$-0.66
Shares (Diluted)
19.2M
+5.7%
18.2M
+17.1%
15.5M
-6.9%
16.7M
+3.9%
16.1M
Elicio Therapeutics (ELTX) โ€” Financials